Depo-Provera (brand name Depo-Provera, manufacturer’s registered trademark, registered active ingredient) is a reversible, synthetic contraceptive indicated for contraception and management of the vaginal and vulvar pain associated with menopause. Depo-Provera is a reversible, synthetic form of the hormone medroxyprogesterone acetate (MPA) and is the only FDA-approved medication to prevent pregnancy for women in the third trimester. Depo-Provera should be taken for at least 7 days in women with the following risk factors: (1) Menopausal symptoms; (2) Vulvovaginal candidiasis (especially candida), cervicitis, or pelvic inflammatory disease (ulcerative colitis, peritonitis, and peritonitis). (3) Menopausal symptoms in women who are pregnant or may become pregnant; (4) A history of infertility; (5) Menopausal symptoms in women with a history of pelvic pain or inflammation, anorexia nervosa, or anorexia, a family history of endometriosis, or pituitary or adrenal carcinoma; (6) Women who are overweight; or who have had a recent stroke, heart attack, or angina (chest pain) and a family history of endometriosis or PCOS.
Depo-Provera is indicated for the treatment of menopausal symptoms in women whose oestrogen receptor (ER) activity is stimulated by estrogens alone or with a combination of estrogen and progestin. In women whose oestrogen receptor is not stimulated by estrogen, or in whom progestin has not been applied, the drug is indicated for the treatment of menopausal symptoms in women whose oestrogen receptor is not stimulated by estrogens alone or with a combination of estrogen and progestin.
Depo-Provera is indicated to be given in doses of 5 mg and 20 mg. The maximum dose of Depo-Provera used is 20 mg per day.
When the dose of Depo-Provera is increased in patients with endometrial cancer, a dose increase of 5 mg daily should be considered when necessary.
In women who are receiving estrogen replacement therapy or for whom progestins are not being used, precautions and warnings should be observed. Women should be encouraged to discuss these risks with their doctor and to ask their doctor any questions about any risks of receiving a progestin that may arise during the treatment of endometriosis.
Oestrogens may increase the risk of hypercalcemia in patients with hypercalcemic conditions. Patients who are receiving progestins and who have hypercalcemia may need a dose adjustment or alternative treatment if they have a hypercalcemic condition.
Because of the potential for hypercalcemia, a dosage adjustment should be considered in women receiving hormonal treatment for endometriosis. If a dosage adjustment is required, the patient should be counseled that dosage adjustments will be made periodically.
The use of Depo-Provera in women who have experienced postmenopausal vaginal bleeding, a recent history of endometriosis, or a family history of endometriosis should be avoided. The use of estrogen therapy should also be avoided in patients who have experienced bleeding episodes from Depo-Provera. In these patients, the risk of hypercalcemia and other serious adverse effects from the use of Depo-Provera is higher than that associated with hormonal therapy for endometriosis.
A recent history of bleeding in women with endometriosis should be discussed with the patient and their doctor to determine the appropriate dosage for their risk of bleeding. The patient should be advised to use the contraceptive until the bleeding episode has stopped and the patient is ready to give birth.
Women who are being treated with Depo-Provera may experience some side effects, including weight gain, breast tenderness, and breast enlargement. Women who are pregnant or may become pregnant should be monitored closely during treatment with Depo-Provera. These effects may be more pronounced in the first half of pregnancy and may be permanent in the last half of the pregnancy.
The Depo-Provera injection contains the synthetic progestogen medroxyprogesterone acetate, which mimics the natural hormone progesterone in the body. Depo-Provera is administered every 3 months and is a good option for women experiencing endometriosis.
If you have ever had an allergic reaction to any of the following medications:
The most common side effects of Depo-Provera are spotting and bleeding at the injection site. More serious side effects may include seizures, anaphylactic reactions, and uterine bleeding. In rare cases, Depo-Provera may cause severe abdominal pain, severe headaches, and changes in the liver function test, including abnormal thyroid function tests, jaundice, and dark urine.
The menstrual cycle is also occasionally disrupted by Depo-Provera. Tell your doctor if you have missed a dose, become dizzy or have a severe headache.
Before starting Depo-Provera, tell your doctor if you are breastfeeding or planning to breastfeed. Depo-Provera passes into breast milk, but it is unlikely to cause harm to a nursing infant. If your doctor prescribes Depo-Provera for your use during a breastfeeding, your baby is unlikely to be affected.
The Canadian drug regulator has approved Depo Provera as the first drug that can prevent pregnancy. Depo-Provera is used to prevent pregnancy by stopping ovulation. In the US, the drug is used to prevent miscarriage in women who have had no other options at all. Depo Provera is also used to treat other types of pregnancy prevention, such as birth control and endometrial or cervical cancer prevention. However, it is also used off-label to treat conditions such as low sperm count, low sperm motility, or poor sperm quality.
The drug's manufacturer, Provera Canada Inc., announced that it has licensed Depo Provera in Canada for use in combination with an alternative, birth control method to reduce the risk of miscarriage. The Canadian drug regulator said that Depo Provera "is not recommended for use in women who have a low sperm count or have a condition that involves high sperm concentrations and/or poor sperm motility." The drug is available by prescription only and may be used with other health care providers if it is appropriate for the individual woman's circumstances. Depo Provera is approved for use in pregnancy by the Canadian government, and it can be used by women who have no other options at all.
"It is important for Canadians to understand that not all options are available to them, and that some are not available or are not effective," said Jim Klee, Chief of the Reproductive Health Branch, the division of reproductive medicine at the University of Alberta. "The Canadian drug regulator will continue to be vigilant for potential drug-drug interactions and will consider all available options when deciding on a drug."
Depo Provera is not recommended for use in women who have a low sperm count or a condition involving high sperm concentrations or poor sperm motility. It is also not recommended for use in women who have a condition that involves high sperm concentration and/or poor sperm motility, or who have a condition that involves low sperm motility.
"This is a serious issue, and Canadians need to weigh the potential benefits against the risks carefully," said Dr. Jean-Pierre Poisson, Depo-Provera's CEO and founder. "We do not recommend this medication for use in women who have a low sperm count or a condition involving high sperm concentration."
The Canadian drug regulator approved Depo-Provera in June for use in pregnant women who have a low sperm count. Depo Provera is currently only used in pregnancy by women with a low sperm count, or with a condition involving high sperm concentrations. The Canadian drug regulator said that the Canadian drug regulator is also evaluating the safety and efficacy of the drug. Depo-Provera should be used by women who have a low sperm count or a condition involving high sperm concentrations.
Depo Provera is a type of hormone called a progestin-like hormone. Depo Provera prevents pregnancy by stopping ovulation and stopping the growth of eggs in the uterus. It also decreases the chance of miscarriage and may even help lower the risk of early-stage miscarriage. The drug is approved for use in pregnancy by the Canadian government, and it can be used by women who have a low sperm count or a condition involving high sperm concentration. Depo-Provera is also used off-label to treat conditions such as low sperm motility, low sperm count, poor sperm motility, or poor sperm motility.The Canadian drug regulator approved Depo-Provera in May for use in pregnant women who have a low sperm count or a condition involving high sperm concentrations. Depo-Provera is also approved for use in women who have a condition involving high sperm concentration or poor sperm motility, or who have a condition involving low sperm concentration.
The Canadian drug regulator also approved Depo-Provera to treat conditions such as low sperm motility, low sperm count, poor sperm motility, or poor sperm motility.
It is also used off-label to treat conditions such as low sperm motility, low sperm count, poor sperm motility, or poor sperm motility.
Depo-Provera prevents pregnancy by stopping ovulation and stopping the growth of eggs in the uterus.The price of Depo-Provera has increased more than 10 percent from last year, and some insurance plans have switched patients to Depo-Provera.
This is the second time in the last four years that the cost of Depo-Provera has gone up more than 10 percent.
The cost of Depo-Provera, a synthetic hormone contraceptive containing the hormone progestin, rose nearly 10 percent in the first six months of last year and will rise to nearly $11,000 by the time it's released.
Depo-Provera is used to treat certain types of women with endometriosis, a type of uterine cancer. In recent years, women who are at risk for developing endometrial cancer have higher rates of breast cancer and a higher risk for endometrial hyperplasia, which can cause pain and tenderness in the pelvic area.
Women who have used birth control pills or have regular unprotected sexual intercourse (HSI) for at least five years and are using Depo-Provera will most likely pay the full price of Depo-Provera, but some plans will add a small extra fee. Some plans, like, also add a small amount to the price of the drug, which is called a depot medroxyprogesterone acetate. It's available as a daily injection.
This price increase was a result of a three-month supply of the drug, which is sold as a generic drug, and some insurance plans switched patients to Depo-Provera from the generic version of the drug. There are currently about 4 million U. S. women using the drug each month, according to the, a health care information company. The price increases have been on the increase for many years.
Some plans will add a monthly fee of up to $4,000 to cover some or all of the cost of the drug. This fee has been shown to increase the price of Depo-Provera from $1,500 to $2,500 for a monthly supply of $2,100. However, some of the plans will add a $3 monthly fee for the drug, which is generally not covered by insurance.
The cost of Depo-Provera is relatively small. The cost of the drug is about $2,800 for a monthly supply, but some plans will add a $3 monthly fee, which is usually covered by insurance. The fee may be a little more than the $3 monthly fee for the drug.
For more information about the price of Depo-Provera and the cost of Depo-Provera, call800-844-3955
We specialize in providing our over 1,000,000 customers with relevant product and condition information created by our professional editorial staff which includes our team of medical writers, medical practitioners, and health educators.
We provide all major credit cards and offer with most major credit cards such as Mastercard, American Express, American Express Pharmacy, American Pharmacy, Citi, Kmart, Zell-Pharmacy, and even some major credit card companies. We offer with most major credit cards such as American Express Pharmacy, American Express Pharmacy, American Express Pharmacy Special, Citi, Kmart, Zell-Pharmacy, and even some major credit card companies.
Stade de France Pharmacy